BC
GNMX

Broadfin Capital’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Broadfin Capital’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-500,000
Closed -$930K – 64
2017
Q1 		$930K Buy
+500,000
New +$2.26M 0.11% 51

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Broadfin Capital's GNMX Position: Q1 2017 in Review

Broadfin Capital sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2017, closing a stake of 3,370,306 shares — an estimated $15.2M sold.

Broadfin Capital first reported a position in GNMX in Q4 2014 and held it in 9 quarters. The position peaked at $18.8M in Q3 2016. 73 funds tracked by Wall St. Rank hold GNMX as of Q1 2017.

  • Broadfin Capital reported no remaining Aevi Genomic Medicine Inc position as of Q1 2017 after selling out during the quarter.
  • Broadfin Capital sold 3,370,306 Aevi Genomic Medicine Inc shares in Q1 2017, an estimated $15.2M.
  • Broadfin Capital first reported a position in Aevi Genomic Medicine Inc in Q4 2014 and held it in 9 quarters.
  • Broadfin Capital's Aevi Genomic Medicine Inc position peaked at $18.8M in Q3 2016.
  • 73 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2017.

Based on Broadfin Capital's 13F filing for Q1 2017, filed 15 May 2017.